KLKenneth Lieberman

Kenneth Lieberman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kenneth Lieberman has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Rethinking Proteinuria: Resolution of Donor Derived EXT2‐Associated Membranous Nephropathy Following Renal Transplantation

    by Mike Fruscione, Devarsh Desai, Satoru Kudose, Yasir Qazi, Samuel Sultan, Kenneth Lieberman, Michael J. Goldstein

    Exostosin‐2 (EXT2)‐associated membranous nephropathy (MN) represents a subgroup of immune complex‐mediated renal diseases, where transplantation may facilitate clearance of immune deposits. We present a successful kidney transplantation from a 19‐year‐old deceased donor with previously undiagnosed EXT2‐associated MN into a 75‐year‐old male recipient. Despite significant pretransplant donor proteinuria (> 300 mg/dL) and hypoalbuminemia, renal biopsies at procurement demonstrated well‐preserved renal architecture with minimal interstitial fibrosis. Clinical follow‐up showed improvement in recipient renal function, with serum creatinine decreasing from 3.56 mg/dL preoperatively to 0.96 mg/dL (reference range: 0.7–1.3 mg/dL) within 2 months posttransplant. Proteinuria, initially nephrotic‐range, progressively resolved to subnephrotic by 4 months. At 6 months, the recipient had normalized renal function and sustained resolution of proteinuria. This case demonstrates that removing a kidney from its native pro‐inflammatory environment, coupled with immunosuppression, can facilitate resolution of immune complex‐mediated glomerulopathy.

  • Daratumumab for Treatment of Acute Antibody‐Mediated Rejection in a Pediatric Kidney Transplant Recipient

    by Hailey Connolly, Ally Watson, Michael Wynd, Kenneth Lieberman, Melissa Chaung, Michael J. Goldstein, Guillermo Hidalgo, Ibrahim Batal, Marlene Amoruso, Namrata G. Jain

    Background: Daratumumab, an anti‐CD38 monoclonal antibody, has shown efficacy as a potential treatment for antibody‐mediated rejection (ABMR) following kidney transplantation in adults. Methods: We present a case demonstrating the use of daratumumab for the management of ABMR in a pediatric kidney transplant recipient. Results: The patient underwent a living‐unrelated donor renal transplant with a post‐transplant course complicated by active ABMR. The patient received a total of four daratumumab infusions with a subsequent decrease in serum creatinine, serum donor‐specific antibody levels, and donor‐derived cell‐free DNA (dd‐cfDNA), which remained low 1 year following treatment. Conclusions: Daratumumab may be a promising treatment consideration for the management of ABMR in pediatric patients following renal transplantation, though further research is needed to better understand its efficacy and side effects. DD‐cfDNA may also be a promising tool to monitor treatment response in conjunction with more traditional methods.


  • CMV‐associated collapsing focal segmental glomerulosclerosis after kidney transplant in a pediatric patient

    by Madeline F. E. Parr, Guillermo Hidalgo, Michael J. Goldstein, Ibrahim Batal, Kenneth V. Lieberman, Marlene R. Amoruso, Aryeh Z. Baer, Namrata G. Jain

    Background: Cytomegalovirus (CMV) is a significant cause of morbidity among immunocompromised patients who have undergone kidney transplantation and is known to rarely induce collapsing focal segmental glomerulosclerosis (FSGS) among adults.Methods: We present the first reported case of CMV‐induced collapsing FSGS in a pediatric patient after kidney transplant.Results: Our patient underwent a deceased donor kidney transplant due to end‐stage renal disease secondary to lupus nephritis. Approximately 4 months after transplantation, he developed signs of worsening kidney function in the setting of CMV viremia and was found to have collapsing features of FSGS on kidney transplant biopsy. He was managed with a prompt escalation of antiviral therapy along with a reduction of immunosuppression and recovered without significant complication. At follow‐up, he continued to have undetectable CMV titers, creatinine within normal limits, and no significant proteinuria.Conclusion: This report demonstrates CMV as a cause of collapsing FSGS and should be considered among pediatric transplant recipients who present with acute kidney injury, as should early assessment of APOL1 genetic status in both donor and recipient.


  • Fulminant recurrence of atypical hemolytic uremic syndrome during a calcineurin inhibitor‐free immunosuppression regimen

    by Sander Florman, Corinne Benchimol, Kenneth Lieberman, Lewis Burrows, Jonathan S. Bromberg

    Recurrence of hemolytic uremic syndrome (HUS) after kidney transplantation is frequent, occurring almost exclusively in patients with atypical HUS, which is not caused by Escherichia coli gastroenteritis and in which diarrhea is absent. Calcineurin inhibitors are associated with recurrence of HUS. In two children who underwent living donor kidney transplantation for atypical HUS, we pre‐emptively employed sirolimus in a calcineurin inhibitor‐free immunosuppression regimen. Both children had excellent early graft function, yet both developed severe recurrent disease and subsequently lost their grafts. Avoidance of calcineurin inhibitors did not prevent recurrence of severe HUS and graft loss. Transplantation for severe atypical HUS remains problematic.